東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Development of a Novel Antibody Drug...

Gromisch, Christopher Marr.

Linked to FindBook

Google Book

Amazon

博客來

Development of a Novel Antibody Drug Conjugate for the Treatment of Pancreatic Adenocarcinoma.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Development of a Novel Antibody Drug Conjugate for the Treatment of Pancreatic Adenocarcinoma./
Author:	Gromisch, Christopher Marr.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2019,
Description:	288 p.
Notes:	Source: Dissertations Abstracts International, Volume: 81-04, Section: B.
Contained By:	Dissertations Abstracts International81-04B.
Subject:	Pharmacology. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13897904
ISBN:	9781687952004

Development of a Novel Antibody Drug Conjugate for the Treatment of Pancreatic Adenocarcinoma.
Gromisch, Christopher Marr.

Development of a Novel Antibody Drug Conjugate for the Treatment of Pancreatic Adenocarcinoma. - Ann Arbor : ProQuest Dissertations & Theses, 2019 - 288 p.

Source: Dissertations Abstracts International, Volume: 81-04, Section: B.

Thesis (Ph.D.)--Boston University, 2019.

This item must not be sold to any third party vendors.

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal common cancer in the United States: in 2017 there will be around 54,000 new cases and 43,000 patient deaths. (SEER, 2017) The high mortality of PDAC is related to late disease presentation and aggressiveness; nearly 52% of patients present with metastatic disease at the time of diagnosis. (SEER, 2017) Current treatments have marginal improvements on survival, with the most efficacious treatment, gemcitabine and nab-paclitaxel, having a median survival of 12.2 months. (Wu 2018) Failure of current PDAC treatments is attributed to the inefficacy of systemic chemotherapeutics and the development of resistance. (Rahib, 2014) The Dual Endothelin1/Signal PeptideVEGF receptor (DEspR), represents a promising therapeutic target for the treatment of PDAC: it is a highly expressed, specific tumor antigen, which is involved in tumor vasculogenesis and cancer stem cell (CSC) survival. DEspR is a developmentally crucial receptor, responsible for early angiogenesis and neural crest migration, with minimal expression in normal adult tissue. In vitro and in vivo studies of anti-DEspR therapy in PDAC have shown efficacy in decreasing CSC survival, tumor angiogenesis, and improving overall survival in xenograft models of PDAC, with anti-DEspR therapy being a promising candidate for clinical use. Furthermore, anti-DEspR therapy seems to augment chemotherapeutic therapy in vitro and in vivo, suggesting that a DEspR-targeted antibody drug conjugate (ADC) would be highly effective. ADCs are a re-emerging drug class with significant promise. Initial failures of ADCs in clinic were related to poor antigen specificity and failures in drug conjugation chemistry to minimally impact the antibody. To develop our ADC, I have developed a novel method of site-specific conjugation that relies on a novel method of supramolecular assembly. My system employs two specific protein sequences that do not self-interact, and tightly assemble through coulombic and hydrophobic interactions, allowing site-specific, stoichiometric self-assembly. To facilitate stable drug delivery, I have synthesized a novel enzymatically cleavable tyrosine-clickable linker, which prevents drug release prior to tumor delivery. Both further investigation into the efficacy of anti-DEspR therapy, and the development of a stoichiometric, site-specific, stable method for drug loading will provide an advancement in anti-cancer therapy.

ISBN: 9781687952004Subjects--Topical Terms:

634543
Pharmacology.
Subjects--Index Terms:

Antibody drug conjugates

Development of a Novel Antibody Drug Conjugate for the Treatment of Pancreatic Adenocarcinoma.
LDR:03692nmm a2200373 4500 001 2266084
005 20200619073038.5
008 220629s2019 ||||||||||||||||| ||eng d
020 $a 9781687952004
035 $a (MiAaPQ)AAI13897904
035 $a AAI13897904
040 $a MiAaPQ $c MiAaPQ
100 1 $a Gromisch, Christopher Marr. $3 3543269
245 1 0 $a Development of a Novel Antibody Drug Conjugate for the Treatment of Pancreatic Adenocarcinoma.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2019
300 $a 288 p.
500 $a Source: Dissertations Abstracts International, Volume: 81-04, Section: B.
500 $a Advisor: Grinstaff, Mark.
502 $a Thesis (Ph.D.)--Boston University, 2019.
506 $a This item must not be sold to any third party vendors.
506 $a This item must not be added to any third party search indexes.
520 $a Pancreatic ductal adenocarcinoma (PDAC) is the most lethal common cancer in the United States: in 2017 there will be around 54,000 new cases and 43,000 patient deaths. (SEER, 2017) The high mortality of PDAC is related to late disease presentation and aggressiveness; nearly 52% of patients present with metastatic disease at the time of diagnosis. (SEER, 2017) Current treatments have marginal improvements on survival, with the most efficacious treatment, gemcitabine and nab-paclitaxel, having a median survival of 12.2 months. (Wu 2018) Failure of current PDAC treatments is attributed to the inefficacy of systemic chemotherapeutics and the development of resistance. (Rahib, 2014) The Dual Endothelin1/Signal PeptideVEGF receptor (DEspR), represents a promising therapeutic target for the treatment of PDAC: it is a highly expressed, specific tumor antigen, which is involved in tumor vasculogenesis and cancer stem cell (CSC) survival. DEspR is a developmentally crucial receptor, responsible for early angiogenesis and neural crest migration, with minimal expression in normal adult tissue. In vitro and in vivo studies of anti-DEspR therapy in PDAC have shown efficacy in decreasing CSC survival, tumor angiogenesis, and improving overall survival in xenograft models of PDAC, with anti-DEspR therapy being a promising candidate for clinical use. Furthermore, anti-DEspR therapy seems to augment chemotherapeutic therapy in vitro and in vivo, suggesting that a DEspR-targeted antibody drug conjugate (ADC) would be highly effective. ADCs are a re-emerging drug class with significant promise. Initial failures of ADCs in clinic were related to poor antigen specificity and failures in drug conjugation chemistry to minimally impact the antibody. To develop our ADC, I have developed a novel method of site-specific conjugation that relies on a novel method of supramolecular assembly. My system employs two specific protein sequences that do not self-interact, and tightly assemble through coulombic and hydrophobic interactions, allowing site-specific, stoichiometric self-assembly. To facilitate stable drug delivery, I have synthesized a novel enzymatically cleavable tyrosine-clickable linker, which prevents drug release prior to tumor delivery. Both further investigation into the efficacy of anti-DEspR therapy, and the development of a stoichiometric, site-specific, stable method for drug loading will provide an advancement in anti-cancer therapy.
590 $a School code: 0017.
650 4 $a Pharmacology. $3 634543
650 4 $a Chemistry. $3 516420
650 4 $a Medicine. $3 641104
650 4 $a Oncology. $3 751006
653 $a Antibody drug conjugates
653 $a Pancreatic cancer
653 $a Supramolecular assembly
690 $a 0419
690 $a 0485
690 $a 0564
690 $a 0992
710 2 $a Boston University. $b Pharmacology GMS. $3 3543270
773 0 $t Dissertations Abstracts International $g 81-04B.
790 $a 0017
791 $a Ph.D.
792 $a 2019
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13897904